Not because of the February cold in Worcester, Mass., but “because I was trying to look bigger and taller ... But it was after that initial preseason cut — Raymond flew home after being waived, then ...
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.